Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Downgraded to “Hold” Rating by Zacks Research

Zacks Research lowered shares of Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) from a strong-buy rating to a hold rating in a report issued on Tuesday morning,Zacks.com reports.

FMS has been the subject of several other research reports. Weiss Ratings raised Fresenius Medical Care AG & Co. KGaA from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Wednesday, October 8th. Bank of America lowered Fresenius Medical Care AG & Co. KGaA from a “neutral” rating to an “underperform” rating in a research note on Wednesday, October 15th. Morgan Stanley reissued an “underweight” rating on shares of Fresenius Medical Care AG & Co. KGaA in a research note on Tuesday, August 12th. Wall Street Zen raised Fresenius Medical Care AG & Co. KGaA from a “buy” rating to a “strong-buy” rating in a research note on Saturday, October 25th. Finally, UBS Group lowered Fresenius Medical Care AG & Co. KGaA from a “sell” rating to an “underperform” rating in a research note on Wednesday, October 15th. One research analyst has rated the stock with a Buy rating, two have given a Hold rating and three have assigned a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Reduce” and an average target price of $30.00.

Fresenius Medical Care AG & Co. KGaA Price Performance

Fresenius Medical Care AG & Co. KGaA stock opened at $24.25 on Tuesday. Fresenius Medical Care AG & Co. KGaA has a one year low of $20.76 and a one year high of $30.46. The business has a fifty day moving average price of $26.03 and a 200-day moving average price of $26.57. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.44 and a quick ratio of 1.08. The firm has a market capitalization of $14.23 billion, a P/E ratio of 19.88, a PEG ratio of 0.64 and a beta of 0.90.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) last posted its quarterly earnings results on Tuesday, November 4th. The company reported $0.64 EPS for the quarter, topping analysts’ consensus estimates of $0.59 by $0.05. Fresenius Medical Care AG & Co. KGaA had a return on equity of 6.75% and a net margin of 3.39%.The firm had revenue of $5.63 billion during the quarter, compared to analyst estimates of $4.72 billion. As a group, equities research analysts forecast that Fresenius Medical Care AG & Co. KGaA will post 1.51 EPS for the current year.

Institutional Investors Weigh In On Fresenius Medical Care AG & Co. KGaA

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Hantz Financial Services Inc. lifted its stake in shares of Fresenius Medical Care AG & Co. KGaA by 220.9% in the 3rd quarter. Hantz Financial Services Inc. now owns 6,671 shares of the company’s stock valued at $176,000 after acquiring an additional 4,592 shares during the last quarter. Searle & CO. lifted its stake in shares of Fresenius Medical Care AG & Co. KGaA by 246.6% in the 3rd quarter. Searle & CO. now owns 80,725 shares of the company’s stock valued at $2,125,000 after acquiring an additional 57,437 shares during the last quarter. DMC Group LLC bought a new stake in shares of Fresenius Medical Care AG & Co. KGaA in the 3rd quarter valued at about $206,000. Evergreen Capital Management LLC lifted its stake in shares of Fresenius Medical Care AG & Co. KGaA by 36.9% in the 3rd quarter. Evergreen Capital Management LLC now owns 11,158 shares of the company’s stock valued at $294,000 after acquiring an additional 3,007 shares during the last quarter. Finally, Forum Financial Management LP increased its holdings in Fresenius Medical Care AG & Co. KGaA by 51.0% during the 3rd quarter. Forum Financial Management LP now owns 13,510 shares of the company’s stock valued at $356,000 after purchasing an additional 4,564 shares during the period. Institutional investors own 8.37% of the company’s stock.

About Fresenius Medical Care AG & Co. KGaA

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.